Richard Zellars named chair of radiation oncology at IU School of Medicine

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

RICHARD ZELLARS was named professor and chair of radiation oncology at the Indiana University School of Medicine, pending approval by the IU trustees. He will begin his new duties in January.

Zellars is a breast cancer research and associate professor of radiation oncology at The Johns Hopkins University, and is assistant director of clinical trial accrual at the Sidney Kimmel Comprehensive Cancer Center. He previously held faculty positions at the University of Texas Health Science Center at San Antonio and Georgetown University.

Zellars’ research focuses on the safety and efficacy of radiation for the treatment of breast cancer. He also does research into health care disparities in African-American women who typically have more severe radiation toxicities. He also founded the Cancer in the Under-Privileged, Indigent or Disadvantaged Summer Fellowship, which exposes first-year medical students who have a demonstrated interest in serving disadvantaged populations to the specialty of oncology.

YOU MAY BE INTERESTED IN

Recently, HHS Secretary Robert F. Kennedy Jr. posted a video montage featuring himself shirtless in jeans, working out with Kid Rock. The duo is in a blue-lit grotto with a cold plunge and sauna. Set to Kid Rock’s “Bawitdaba” and intercut with a selection of patriotic imagery, the video ends with the two men in a hot tub, chugging what appears to be milk.
In January, FDA released a draft guidance entitled “Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval.” This release came roughly 20 months after the Oncologic Drugs Advisory Committee (ODAC) voted unanimously that minimal residual disease (MRD) negativity, in combination with complete response (CR), is an acceptable primary endpoint to support accelerated approval for multiple myeloma (MM) therapies. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login